 CAMBRIDGE, Mass., Nov. 04, 2020 GLOBE NEWSWIRE -- AlloVir Nasdaq: ALVR, a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that support its pipeline of allogeneic, off-the-shelf virus-specific T cell therapies during the 62nd American Society of Hematology ASH Annual Meeting Exposition taking place virtually December 5 8, 2020. 